Nov 2026· American Journal of Kidney Diseases· 0 citations· 16 references
Medicine
TL;DR
Integrating dd-cfDNA, transcriptomic biopsy analysis, and non-HLA antibody assessment may optimize the management of highly sensitized KT recipients following imlifidase induction, however, long-term efficacy remains to be confirmed.
Abstract
A highly sensitized patient received a kidney transplant (KT) following imlifidase induction: we report an innovative diagnostic and therapeutic strategy for rejection management. On day 20 post-KT, the patient developed acute kidney injury, with donor-derived cell-free DNA (dd-cfDNA) increasing to 1.93%. Histology revealed isolated glomerulitis (g1) with C4d(2+) deposits along peritubular capillaries. Steroids and plasma exchanges were administered for suspected antibody-mediated rejection (AMR), despite no rebound of donor-specific anti-HLA antibodies (DSAs). Non-HLA anti-endothelial cell antibodies were positive, confirming AMR according to Banff 2022. Transcriptomic analysis showed overexpression of complement pathway-associated transcripts. C5 inhibition failed as serum creatinine further increased along with dd-cfDNA (3.96%). A second biopsy confirmed active AMR with increased expression of NK-related transcripts, leading to anti-CD38 treatment (daratumumab). At 6 months post-KT, the condition was controlled with stable creatinine at 20.4 μg/mL, dd-cfDNA decreased to 0.1%, microvascular inflammation resolved, non-HLA anti-endothelial cell antibodies became undetectable, still without HLA DSA rebound. Daratumumab is ongoing. Integrating dd-cfDNA, transcriptomic biopsy analysis, and non-HLA antibody assessment may optimize the management of highly sensitized KT recipients following imlifidase induction. However, long-term efficacy remains to be confirmed.
Imlifidase, an IgG-cleaving enzyme, offers a novel desensitization strategy for highly sensitized kidney-transplant candidates with donor-specific antibodies (DSA). We report the first Belgian kidney recipient with a positive virtual crossmatch and treated with a single dose of imlifidase prior to transplantation. HLA...
Justine Schmitt, C. Bonvoisin, A. Bouquegneau et al.· Human Immunology· 0 citations
This review summarizes current concepts in AMR pathogenesis, diagnosis, and emerging therapy, using phenotype-guided assessment to separate expert-consensus practice from randomized evidence, observational experience, and experimental interventions.
Bi-Du Song, Jun-Jie Sun, Chao Hu et al.· Frontiers in Immunology· 0 citations
This case highlights CD38 blockade as a potential therapeutic option in selected patients with concomitant AMR and BKPyVAN and given the concurrent administration of corticosteroids and optimization of maintenance immunosuppression, these findings should be regarded as hypothesis-generating.
Shuyang Traub, T. Menter, Stefan Schaub et al.· Kidney360· 0 citations
Background/Objectives: Plasma cell-rich rejection (PCRR) is a severe form of liver allograft dysfunction that can lead to graft failure and re-transplantation. Often overlapping with antibody-mediated rejection (AMR) and T-cell-mediated rejection (TCMR), PCRR remains under-researched regarding its predisposing risk fac...
T. D. Clara Nguyen, B. Langlais, C. Jayasekera et al.· Biomedicines· 0 citations
The presence of HLA donor-specific antibodies (DSAs), both before and after transplantation, is a well-established risk factor for antibody-mediated rejection (AMR) and poor graft survival. However, emerging evidence suggests that non-HLA antibodies may also provoke immune responses, contributing to rejection. Among th...
Annika Sundlof, M. Taniguchi, Rohit Gupta et al.· International Journal of Mol...· 0 citations
Immune-mediated injury to a renal allograft remains one of the leading causes of graft loss in the late post-transplant period. Modern transplantation immunology considers rejection as a complex multilevel process involving cellular, humoral, and molecular mechanisms of the alloimmune response. This paper reviews curre...
V. Torak· Clinical and experimental pa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.